RGNXREGENXBIO Inc.
$8.08-23% 1Y
$8.08
$5.6552 weeks$15.98
The financials
REGENXBIO Inc. by the numbers
REGENXBIO Inc. (RGNX) reported revenue of $108M in Q2 2026 (quarter ended Jun 30, 2026), up 406% from the same quarter a year earlier. That came with net income of $23M (21% of revenue). For the full year FY2025, revenue was $170M (+105% year on year) and net income −$194M. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $108M | $21M | +406% |
| Operating income | $29M | −$63M | to a profit |
| Net income | $23M | −$71M | to a profit |
| Diluted EPS | $0.43 | −$1.38 | to a profit |